{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:01:38Z","timestamp":1789578098586,"version":"build-2803163510"},"reference-count":50,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2014,3,13]],"date-time":"2014-03-13T00:00:00Z","timestamp":1394668800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0090675","type":"journal-article","created":{"date-parts":[[2014,3,13]],"date-time":"2014-03-13T20:48:15Z","timestamp":1394743695000},"page":"e90675","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":28,"title":["Purine Analog-Like Properties of Bendamustine Underlie Rapid Activation of DNA Damage Response and Synergistic Effects with Pyrimidine Analogues in Lymphoid Malignancies"],"prefix":"10.1371","volume":"9","author":[{"given":"Nobuya","family":"Hiraoka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiro","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Yamauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Koyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taeko","family":"Wada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuyo","family":"Uesawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miyuki","family":"Akutsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigehisa","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiko","family":"Kano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Furukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2014,3,13]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00280-010-1317-x","article-title":"Bendamustine: something old, something new","volume":"66","author":"N Tageja","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/0005-2787(72)90282-1","article-title":"Investigation of cross-link formation in DNA by the alkylating cytostatic IMET 3106, 3393 and 3943","volume":"287","author":"M Hartmann","year":"1972","journal-title":"Biochim Biophys Acta"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/00001813-199606000-00007","article-title":"Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines","volume":"7","author":"D Strumberg","year":"1996","journal-title":"Anticancer Drugs"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1158\/1078-0432.CCR-07-1061","article-title":"Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents","volume":"14","author":"LM Leoni","year":"2008","journal-title":"Clin Cancer Res"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1038\/sj.leu.2402651","article-title":"In vitro evaluation of bendamustine induced apoptosis in B-chronic lymphocytic leukemia","volume":"16","author":"C Schw\u00e4nen","year":"2002","journal-title":"Leukemia"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"6907","DOI":"10.1158\/1078-0432.CCR-08-0388","article-title":"Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling","volume":"14","author":"G Rou\u00e9","year":"2008","journal-title":"Clin Cancer Res"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"e40342","DOI":"10.1371\/journal.pone.0040342","article-title":"Dose dependent effects on cell cycle checkpoints and DNA repair by bendamustine","volume":"7","author":"N Beeharry","year":"2012","journal-title":"PLoS ONE"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"4378","DOI":"10.1200\/JCO.2008.20.8389","article-title":"Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia","volume":"27","author":"WU Knauf","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1200\/JCO.2007.12.5070","article-title":"Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin\u2019s lymphoma: results from a phase II multicenter, single-agent study","volume":"26","author":"JW Friedberg","year":"2008","journal-title":"J Clin Oncol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1200\/JCO.2008.17.0001","article-title":"Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin\u2019s lymphoma","volume":"26","author":"KS Robinson","year":"2008","journal-title":"J Clin Oncol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicetre, randomised, phase 3 non-inferiority trial","volume":"381","author":"MJ Rummel","year":"2013","journal-title":"Lancet"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1200\/JCO.2012.46.5203","article-title":"Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma","volume":"31","author":"K Ohmachi","year":"2013","journal-title":"J. Clin Oncol"},{"key":"ref13","first-page":"184","article-title":"Safe and effective treatment of aggressive non-Hodgkin lymphoma with rituximab and bendamustine in patients with severe liver impairment","volume":"11","author":"JK McCloskey","year":"2013","journal-title":"Clin Adv Hematol Oncol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00277-013-1751-z","article-title":"Rituximab, bendamustine, and lenalidomide in patients with aggressive B cell lymphoma not eligible for high-dose chemotherapy or anthracycline-based therapy: phase I results of the SAKK 38\/08 trial","volume":"92","author":"F Hitz","year":"2013","journal-title":"Ann Hematol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"4608","DOI":"10.1182\/blood-2011-12-395715","article-title":"Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1\/2 open-label, dose escalation study","volume":"119","author":"S Lentzsch","year":"2012","journal-title":"Blood"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"e162","DOI":"10.1038\/bcj.2013.58","article-title":"Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study","volume":"3","author":"M Offidani","year":"2013","journal-title":"Blood Cancer J"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1200\/JCO.2012.43.7285","article-title":"Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial","volume":"31","author":"G Damaj","year":"2013","journal-title":"J Clin Oncol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"611","DOI":"10.2165\/00044011-200424100-00007","article-title":"Carboplatin in combination with bendamustine in previously untreated patients with extensive-stage small cell lung cancer (SCLC)","volume":"24","author":"W K\u00f6ster","year":"2004","journal-title":"Clin Drug Investig"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1007\/s00280-013-2112-2","article-title":"Severe and prolonged lymphopenia observed in patients treated with bendamustine and erlotinib for metastatic triple negative breast cancer","volume":"71","author":"RM Layman","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref20","first-page":"485","article-title":"<italic>In vitro<\/italic> induction of apoptosis of neoplastic cells in low-grade non-Hodgkin\u2019s lymphomas using combinations of established cytotoxic drugs with bendamustine","volume":"86","author":"KU Chow","year":"2001","journal-title":"Haematologica"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S0006-2952(03)00410-6","article-title":"Synergistic effects of chemotherapeutic drugs in lymphoma cells are associated with down-regulation of inhibitor of apoptosis proteins (IAPs), prostate-apoptosis-response-gene 4 (Par-4), death-associated protein (Daxx) and with enforced caspase activation","volume":"66","author":"KU Chow","year":"2003","journal-title":"Biochem Pharmacol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.3109\/10428194.2012.688200","article-title":"Cytosine arabinoside potentiates the apoptotic effect of bendamustine on several B- and T-cell leukemia\/lymphoma cells and cell lines","volume":"53","author":"S Castegnaro","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.bcmd.2011.09.007","article-title":"The cytotoxic effects of bendamustine in combination with cytarabine in mantle lymphoma cell lines","volume":"48","author":"C Visco","year":"2012","journal-title":"Blood Cell Mol Dis"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.canlet.2013.02.046","article-title":"Combination of bendamustine and entinostat synergistically inhibits proliferation of multiple myeloma cells via induction of apoptosis and DNA damage response","volume":"335","author":"B Cai","year":"2013","journal-title":"Cancer Lett"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1080\/1042819042000223822","article-title":"Fludarabine and bendamustine in refractory and relapsed indolent lymphoma - multicenter phase I\/II trial of the East German Society of Hematology and Oncology (OSHO)","volume":"45","author":"M Koenigsmann","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1080\/10428190701361828","article-title":"German Low Grade Lymphoma Study Group: High anti-lymphoma activity of bendamustine\/mitoxantrone\/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG)","volume":"48","author":"R Weide","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1200\/JCO.2012.45.9842","article-title":"Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation","volume":"31","author":"C Visco","year":"2013","journal-title":"J Clin Oncol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/ajh.23391","article-title":"The combination of rituximab, bendamustine, and cytarabine for heavily pretreated relapsed\/refractory cytogenetically high-risk patients with chronic lymphocytic leukemia","volume":"88","author":"C Visco","year":"2013","journal-title":"Am J Hematol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/1097-0142(19880201)61:3<483::AID-CNCR2820610313>3.0.CO;2-L","article-title":"Characterization and comparison of two newly established Epstein-Barr virus-negative lymphoma B-cell lines. Surface markers, growth characteristics, cytogenetics, and transplantability","volume":"61","author":"M Abe","year":"1988","journal-title":"Cancer"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"e169","DOI":"10.1038\/bcj.2013.66","article-title":"Alkylating agents induce histone H3K18 hyperacetylation and potentiate HDAC inhibitor-mediated global histone acetylation and cytotoxicity in mantle cell lymphoma","volume":"3","author":"N Hiraoka","year":"2013","journal-title":"Blood Cancer J"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/sj.leu.2404593","article-title":"Divergent cytotoxic effects of PKC412 in combination with conventional antileukemic agents in FLT3 mutation-positive versus -negative leukemia cell lines","volume":"21","author":"Y Furukawa","year":"2007","journal-title":"Leukemia"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Koyama D, Kikuchi J, Hiraoka N, Wada T, Kurosawa H, <etal>et al<\/etal>.. (2014) Proteasome inhibitors exert cytotoxicity and increase chemosensitivity via transcriptional repression of Notch1 in T-cell acute lymphoblastic leukemia. Leukemia, advanced online publication, 17 January 2014; doi:10.1038\/leu.2013.366.","DOI":"10.1038\/leu.2013.366"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/sj.leu.2401633","article-title":"Enhancement of retention and cytotoxicity of 2-chlorodeoxyadenosine in cultured human leukemic lymphoblasts by nitrobenzylthioinosine, an inhibitor of equilibrative nucleoside transport","volume":"14","author":"AMP Wright","year":"2000","journal-title":"Leukemia"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"25593","DOI":"10.1074\/jbc.M113.480574","article-title":"The novel orally active proteasome inhibitor K-7174 exerts anti-myeloma activity <italic>in vitro<\/italic> and <italic>in vivo<\/italic> by down-regulating the expression of class I histone deacetylases","volume":"288","author":"J Kikuchi","year":"2013","journal-title":"J Biol Chem"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1016\/j.bcp.2009.03.011","article-title":"Intracellular cytarabine triphosphate production correlates to deoxycytidine kinase\/cytosolic 5\u2032-nucleotidase II expression ratio in primary acute myeloid leukemia cells","volume":"77","author":"T Yamauchi","year":"2009","journal-title":"Biochem Pharmacol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1016\/j.bcp.2005.03.013","article-title":"A sensitive new method for clinically monitoring cytarabine concentrations at the DNA level in leukemia cells","volume":"69","author":"T Yamauchi","year":"2005","journal-title":"Biochem Pharmacol"},{"key":"ref37","first-page":"1800","article-title":"A new sensitive method for determination of intracellular 1-\u00df-D-arabinofuranosylcytosine 5\u2032-triphosphate content in human materials <italic>in vivo<\/italic>","volume":"56","author":"T Yamauchi","year":"1996","journal-title":"Cancer Res"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1038\/sj.bjc.6603776","article-title":"A phase I study of bendamustine hydrochloride administered day 1+2 every 3 weeks in patients with solid tumours","volume":"96","author":"M Rasschaert","year":"2007","journal-title":"Br J Cancer"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1111\/j.1349-7006.2010.01633.x","article-title":"Phase I and pharmacokinetic study of bendamustine hydrochloride in relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma","volume":"101","author":"M Ogura","year":"2010","journal-title":"Cancer Sci"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/0006-2952(72)90322-X","article-title":"Studies on the transport and cellular distribution of chlorambucil in the Yoshida ascites sarcoma","volume":"21","author":"BT Hill","year":"1972","journal-title":"Biochem Pharmacol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1021\/jm00157a015","article-title":"<sup>31<\/sup>P nuclear magnetic resonance spectroscopic observation of the intracellular transformations of oncostatic cyclophosphamide metabolites","volume":"29","author":"VL Boyd","year":"1986","journal-title":"J Med Chem"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/sj.leu.2403271","article-title":"Nucleoside transporters in chronic lymphocytic leukemia","volume":"18","author":"M Pastor-Anglada","year":"2004","journal-title":"Leukemia"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1080\/15257770.2011.597372","article-title":"Translocation of nucleoside analogs across the plasma membrane in hematologic malignancies","volume":"30","author":"PX Fernandez-Calotti","year":"2011","journal-title":"Nucleosides, Nucleotides and Nucleic Acids"},{"key":"ref44","first-page":"63a","article-title":"In-vitro modulation of Ara-CTP accumulation in fresh AML cells by bendamustine in comparison with fludarabine, 2-CDA and gemcitabine","volume":"94","author":"P Staib","year":"1999","journal-title":"Blood"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1182\/blood.V87.1.256.256","article-title":"Chlorodeoxyadenosine and arbinosylcytosine in patients with acute myelogenous leukemia: Pharmacokinetic, pharmacodynamic, and molecular interactions","volume":"87","author":"V Gandhi","year":"1996","journal-title":"Blood"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1080\/1042819021000054670","article-title":"In AML cell lines Ara-C combined with purine analogues is able to exert synergistic as well as antagonistic effects on proliferation, apoptosis and disruption of mitochondrial membrane potential","volume":"44","author":"KU Chow","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1600-0609.1996.tb01932.x","article-title":"Nucleoside transporters, bcl-2 and apoptosis in CLL cells exposed to nucleoside analogues <italic>in vitro<\/italic>","volume":"56","author":"AJ Petersen","year":"1996","journal-title":"Eur J Haematol"},{"key":"ref48","first-page":"6421","article-title":"Clinical pharmacokinetics of cyclophosphamide and metabolites with and without SR-2508","volume":"54","author":"KK Chan","year":"1994","journal-title":"Cancer Res"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00432-005-0023-2","article-title":"Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin\u2019s lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19)","volume":"132","author":"M Herold","year":"2006","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1182\/blood-2011-04-351924","article-title":"BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant\/relapsed lymphoma patients","volume":"118","author":"G Visani","year":"2011","journal-title":"Blood"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0090675","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,16]],"date-time":"2020-08-16T08:48:11Z","timestamp":1597567691000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0090675"}},"subtitle":[],"editor":[{"given":"Tadayuki","family":"Akagi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,3,13]]},"references-count":50,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2014,3,13]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0090675","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,13]]}}}